Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
147
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Comparison Of Methods To Estimate Disease-Related Cost And Healthcare Resource Utilization For Autoimmune Diseases In Administrative Claims Databases

Krista M Schroeder1 Global Patient Outcomes – Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USACorrespondence[email protected]
View further author information
,
Steve Gelwicks1 Global Patient Outcomes – Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USAView further author information
,
April N Naegeli1 Global Patient Outcomes – Real World Evidence, Eli Lilly and Company, Indianapolis, IN, USAView further author information
&
Pamela C Heaton2 James L. Winkle College of Pharmacy, University of Cincinnati Academic Health Center, Cincinnati, OH, USAView further author information
Pages 713-727 | Published online: 26 Nov 2019

Citations (4)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Nassir Azimi, Freddy Caldera, Stan Cohen, James Conners, Timothy Fernandes, May Han, Vibeke Strand, Victor Tapson, Aaron Weinberg, Jeffrey Weinberg & Andres Yarur. (2021) Immune-mediated diseases and thromboembolic events: a modified Delphi panel. Current Medical Research and Opinion 37:8, pages 1283-1291.
Read now
Jeffrey S. Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre & Veronica Ashton. (2021) Healthcare resource utilization and costs of rivaroxaban versus warfarin among non-valvular atrial fibrillation (NVAF) patients with obesity in a US population. Journal of Medical Economics 24:1, pages 550-562.
Read now

Articles from other publishers (2)

Jeffrey S. Berger, François Laliberté, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre & Veronica Ashton. (2022) Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States. Journal of Thrombosis and Thrombolysis 54:3, pages 438-448.
Crossref
François Laliberté, Veronica Ashton, Akshay Kharat, Dominique Lejeune, Kenneth Todd Moore, Young Jung, Patrick Lefebvre & Jeffrey S Berger. (2021) Economic burden of rivaroxaban and warfarin among nonvalvular atrial fibrillation patients with obesity and polypharmacy. Journal of Comparative Effectiveness Research 10:16, pages 1235-1250.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.